

DI-059

USE, EFFECTIVENESS AND SAFETY OF IVABRADINE IN PEDIATRIC PATIENTS

I. Marquínez Alonso, S. Manrique-Rodríguez, C.M. Fernández-Llamazares, A. Ribed, S. Buendía-Bravo,

P. Arrabal-Durán, X. García-González, M. Tovar-Pozo, M. Sanjurjo Sáez

Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

BACKGROUND


Ivabradine is authorized for the treatment of coronary artery disease and chronic heart failure with


systolic dysfunction in adult patients, but there is little information on its efficacy and safety in pediatric population.

PURPOSE

To assess the use, effectiveness and safety of ivabradine in pediatric patients.

MATERIALS AND METHODS







RESULTS

PATIENTS' CHARACTERISTICS

Ν	4
Indication: Innapropriate sinus tachycardia	4 (100%)
Median age (years)	5.6 (1.1 – 15.5)
Median starting dose (mg/kg)	0,08 mg/kg/12h



Effect of ivabradine on heart rate (HR)



CONCLUSIONS

Ivabradine seemed to be an effective and safe treatment for inappropriate sinus tachycardia in most of our pediatric patients. Nonetheless, more studies are required to confirm these results.

iratxe.marquinez@salud.madrid.org

Barcelona, 26-28 March 2014